Drugs Containing Excipient (Inactive Ingredient) HYPROMELLOSE 2910

« Back to Dashboard

Branded drugs containing HYPROMELLOSE 2910 excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	EFFIENT	prasugrel hydrochloride	0002-5121	HYPROMELLOSE 2910
Genentech Inc	VALCYTE	valganciclovir	0004-0038	HYPROMELLOSE 2910
Genentech Inc	XELODA	capecitabine	0004-1100	HYPROMELLOSE 2910
Merck Sharp & Dohme LLC	JANUMET	sitagliptin and metformin hydrochloride	0006-0078	HYPROMELLOSE 2910
Merck Sharp & Dohme Corp	ZOCOR	simvastatin	0006-0543	HYPROMELLOSE 2910
Merck Sharp & Dohme LLC	ZEPATIER	elbasvir and grazoprevir	0006-3074	HYPROMELLOSE 2910	2029-07-24

Generic drugs containing HYPROMELLOSE 2910 excipient

Company	Ingredient	NDC	Excipient
Eli Lilly and Company	prasugrel hydrochloride	0002-5121	HYPROMELLOSE 2910
Genentech Inc	valganciclovir	0004-0038	HYPROMELLOSE 2910
Genentech Inc	capecitabine	0004-1100	HYPROMELLOSE 2910
Merck Sharp & Dohme LLC	sitagliptin and metformin hydrochloride	0006-0078	HYPROMELLOSE 2910
Merck Sharp & Dohme Corp	simvastatin	0006-0543	HYPROMELLOSE 2910
Merck Sharp & Dohme LLC	elbasvir and grazoprevir	0006-3074	HYPROMELLOSE 2910

Hypromellose 2910 Market Dynamics and Financial Trajectory

Last updated: September 28, 2026

Hypromellose 2910, also known as hydroxypropyl methylcellulose or HPMC 2910, is a compendial pharmaceutical excipient used in film coating, tablet binding, controlled-release matrices, hard capsules, ophthalmic products, and other oral and topical dosage forms. Its market is expanding with generic-drug production, vegetarian capsules, modified-release formulations, and demand for high-purity pharmaceutical excipients.

The market has favorable structural growth but limited public financial transparency. Producers generally report HPMC within broader cellulose-derivative, pharmaceutical-excipient, or specialty-ingredients segments rather than as a standalone product. Revenue growth is therefore best assessed through volume demand, price realization, capacity investments, formulation adoption, and supplier mix rather than a single audited HPMC 2910 market figure.

What is Hypromellose 2910 and how is it used?

Hypromellose 2910 is a cellulose ether produced by chemically modifying purified cellulose. The "2910" designation identifies the substitution profile: approximately 19% to 24% methoxy substitution and 7% to 12% hydroxypropoxy substitution under the United States Pharmacopeia classification.[1]

Its commercial value comes from its ability to control viscosity, film formation, water penetration, tablet cohesion, and drug-release kinetics.

Application	Function of HPMC 2910	Commercial relevance
Immediate-release tablets	Binder and film former	Supports high-volume generic manufacturing
Film coating	Protective and cosmetic coating polymer	Reduces friability and improves swallowability
Extended-release tablets	Hydrophilic matrix former	Enables controlled drug release
Hard capsules	Capsule-shell polymer	Supports vegetarian and non-gelatin dosage forms
Ophthalmic products	Viscosity modifier and lubricant	Used in artificial tears and topical formulations
Multiparticulates and pellets	Coating and release-control polymer	Used in complex oral delivery systems
Nutraceuticals	Capsule and coating material	Extends demand beyond prescription pharmaceuticals

HPMC 2910 is not an active pharmaceutical ingredient. It does not have therapeutic exclusivity, patent-based market protection, or an Orange Book listing.

What are the key chemical and regulatory specifications for HPMC 2910?

HPMC 2910 is typically specified by substitution type, viscosity grade, particle-size distribution, loss on drying, residue on ignition, heavy metals or elemental impurities, microbial quality, and residual solvents.

Common commercial grades differ mainly in viscosity and particle engineering. Low-viscosity grades are used in film coatings and binders. Higher-viscosity grades are used in extended-release matrices and gel-forming systems.

Core regulatory identifiers

Attribute	HPMC 2910 status
Chemical name	Hydroxypropyl methylcellulose
Common name	Hypromellose
CAS number	9004-65-3
USP-NF name	Hypromellose
Substitution type	2910
European Pharmacopoeia	Hypromellose monograph
Japanese Pharmacopoeia	Hypromellose monograph
FDA status	Inactive ingredient accepted in approved drug products, subject to product-specific conditions
Drug category	Pharmaceutical excipient
Orange Book status	Not listed as an active ingredient
Paragraph IV exposure	None as an excipient product
Biosimilar exposure	None directly

FDA’s Inactive Ingredient Database records excipient use in approved drug products by dosage form, route, and maximum potency. That database supports regulatory precedent but does not confer exclusivity on a supplier or product grade.[2]

HPMC 2910 manufacturers also manage compliance with ICH Q3C residual-solvent limits, ICH Q3D elemental-impurity requirements, current good manufacturing practices, and excipient-supply-chain qualification standards.[3][4]

How large is the HPMC 2910 market?

A standalone global market figure for pharmaceutical-grade HPMC 2910 is not consistently disclosed by public companies or regulators. Commercial market reports often combine pharmaceutical HPMC with industrial cellulose ethers, food-grade hydrocolloids, construction-grade polymers, or all hypromellose substitution types. Those categories are not directly interchangeable.

The addressable market is best divided into four layers:

1. Pharmaceutical-grade HPMC 2910.
2. Other pharmaceutical hypromellose substitution types, including HPMC 2906 and 2208.
3. Non-pharmaceutical HPMC used in construction, food, personal care, and industrial applications.
4. Finished dosage forms that consume HPMC 2910, including tablets and capsules.

Pharmaceutical HPMC 2910 is a smaller segment than total HPMC production, but it carries higher qualification requirements and generally higher average selling prices than industrial material. A producer with a diversified HPMC portfolio can shift production between end markets, which reduces exposure to a single pharmaceutical cycle but also makes segment-level revenue difficult to isolate.

Demand indicators

Demand driver	Effect on HPMC 2910
Generic-drug volume growth	Increases tablet, coating, and matrix-polymer consumption
Vegetarian capsule adoption	Expands demand for HPMC capsule-shell material
Controlled-release formulation growth	Raises demand for high-viscosity grades
Oral solid dosage dominance	Supports long-term baseline demand
Contract manufacturing growth	Increases multi-site qualification activity
Excipient substitution	Creates opportunities where formulators replace gelatin, PVP, or other polymers
Biologics growth	Limited direct effect because HPMC is primarily an oral-solid-dosage excipient
Pharmaceutical inventory destocking	Can produce short-term order volatility

The strongest demand is tied to oral solid dosage manufacturing rather than innovative biologics. HPMC 2910 is therefore exposed to generic-drug volumes, contract-development activity, and manufacturing geography.

Which companies manufacture pharmaceutical-grade HPMC 2910?

The main competitive field includes multinational specialty-chemical companies and large Asian cellulose-derivative producers.

Company	Relevant product or platform	Competitive position
Shin-Etsu Chemical	Pharmacoat and related pharmaceutical cellulose derivatives	Strong pharmaceutical qualification and global formulation presence
Dow	METHOCEL pharmaceutical grades	Broad excipient portfolio and established regulatory support
Ashland	Benecel and related pharmaceutical excipients	Formulation support and specialty-excipient distribution
Lotte Fine Chemical	Pharmaceutical-grade cellulose ethers, including AnyCoat-related offerings	Large-scale Asian manufacturing and global supply
SE Tylose	Pharmaceutical cellulose ethers	European production and specialty-grade supply
Colorcon	Film-coating systems incorporating hypromellose	Downstream formulation and coating-system integration
Capsule manufacturers	HPMC capsule products using qualified cellulose polymers	Important demand channel rather than direct polymer competition

Shin-Etsu’s Pharmacoat brand is widely used in pharmaceutical coating and solid-dosage development. Dow’s METHOCEL portfolio covers multiple substitution types and viscosity levels. Ashland and Lotte Fine Chemical compete through grade breadth, technical service, quality documentation, and regional supply.

The competitive basis is not only price. Drug manufacturers evaluate supplier consistency across viscosity, substitution ratio, particle size, microbial limits, residual solvents, lot-to-lot performance, and documentation.

How strong is the patent and intellectual-property position for HPMC 2910?

HPMC 2910 is a mature excipient with limited composition-of-matter exclusivity. The product itself is generally available from multiple suppliers and is not protected by a single controlling patent estate.

The most important intellectual-property barriers are process know-how, manufacturing conditions, grade engineering, analytical methods, customer qualification data, and formulation patents.

Relevant IP categories

IP category	Importance
HPMC chemical composition	Low, because the material is mature and broadly commercialized
Manufacturing process	Moderate to high; controls substitution uniformity, viscosity, purity, and yield
Grade-specific particle engineering	Moderate
Controlled-release formulations	High in selected drug products
Film-coating systems	Moderate, particularly for proprietary premixes
HPMC capsule-shell technology	Moderate
Analytical and quality-control methods	Moderate
Supplier qualification history	High in practice, despite limited formal exclusivity

Drug-specific patents can cover the use of HPMC 2910 in a particular release profile, dosage form, or combination. Those patents protect the finished product or formulation, not the excipient as a general material.

Manufacturers therefore compete primarily through manufacturing scale, quality systems, supply reliability, technical support, and regulatory history. Process patents may exist, but much of the commercial advantage is likely to reside in trade secrets and operational know-how.

What is the regulatory status of HPMC 2910 in the United States and Europe?

HPMC 2910 is a recognized pharmaceutical excipient with established compendial use. It is not approved through the same pathway as a drug substance.

United States

In the United States, HPMC 2910 is used in FDA-approved drug products as an inactive ingredient. Its acceptability depends on route, dosage form, concentration, manufacturing quality, and the specific drug application. Sponsors must identify the excipient and its supplier in the relevant submission.

A supplier may provide a Drug Master File or equivalent confidential quality documentation, but the FDA does not grant a general product exclusivity period for HPMC 2910.

European Union

European manufacturers rely on the European Pharmacopoeia monograph, qualified supplier controls, and the quality section of the marketing-authorization application. The European framework also places emphasis on excipient risk assessment and supplier qualification under EU good manufacturing practice requirements.[5]

Global markets

Japan, China, India, and other regulated markets recognize hypromellose in national pharmacopeias or accept it under established excipient frameworks. Regional differences remain in monograph testing, documentation, import controls, change notification, and local manufacturing expectations.

Geographic coverage is a competitive advantage because customers prefer suppliers able to support regulatory filings across the United States, European Union, Japan, China, and emerging markets.

When does HPMC 2910 lose exclusivity?

HPMC 2910 does not have a fixed patent or regulatory exclusivity date. It is a mature, multisource excipient.

There is no:

• Orange Book exclusivity period for HPMC 2910;
• Paragraph IV process directed to HPMC 2910 itself;
• biosimilar pathway associated with the material;
• statutory launch date after which competitors may enter;
• single patent expiration date governing supply.

Commercial exclusivity can still exist at the customer level. A drug sponsor may qualify one supplier for a specific product and maintain that source for years. A supplier’s grade may also be embedded in a formulation development history, making substitution costly even when legally available.

What is the financial trajectory for pharmaceutical HPMC 2910?

The financial trajectory is likely to show moderate volume growth, periodic price volatility, and stable but differentiated margins for qualified pharmaceutical grades.

Public companies generally do not report HPMC 2910 revenue separately. Dow reports broad business segments, Ashland reports specialty-ingredients categories, Shin-Etsu reports cellulose derivatives within wider businesses, and Lotte Fine Chemical reports broader chemical operations. Product-level revenue, gross margin, and EBITDA for pharmaceutical HPMC 2910 are therefore not directly observable in public filings.[6][7][8][9]

Financial drivers

Driver	Financial effect
Cellulose-pulp costs	Influences gross margin and pricing
Chloromethane and propylene-oxide costs	Affects conversion cost
Energy and utilities	Important for drying and processing economics
Capacity utilization	Strong determinant of unit cost
Pharmaceutical qualification	Supports pricing premium
Generic-drug pricing pressure	Limits pass-through in high-volume products
Supply-chain redundancy	Supports customer retention
Regional production	Reduces freight and trade exposure
Grade mix	Higher-purity and higher-viscosity grades may improve margins
Currency movements	Affect multinational supplier reporting

Pharmaceutical-grade material generally has better pricing than industrial HPMC because it requires validated manufacturing, tighter specifications, extensive documentation, and customer audits. The margin premium is constrained by the availability of qualified alternatives and the ability of large pharmaceutical buyers to negotiate globally.

Base-case trajectory

Period	Expected market behavior
Near term	Inventory normalization, price competition in standard grades, continued demand from generics
Medium term	Growth in modified-release tablets, HPMC capsules, and emerging-market drug production
Longer term	Stable oral-solid-dosage demand with increased supplier qualification and regionalization

The strongest financial performance should occur in differentiated pharmaceutical grades, high-viscosity matrix polymers, capsule-shell materials, and integrated film-coating systems. Commodity-like standard grades face greater price pressure, particularly where Chinese and Indian suppliers expand capacity.

What manufacturing barriers affect HPMC 2910 supply?

HPMC 2910 production requires more than cellulose etherification. Pharmaceutical suppliers must maintain consistent substitution, viscosity, moisture, microbial quality, and particle characteristics across commercial batches.

Key barriers include:

• access to consistent dissolving-grade cellulose;
• controlled etherification chemistry;
• removal of salts and reaction by-products;
• solvent recovery and residual-solvent control;
• narrow viscosity specifications;
• validated cleaning and contamination controls;
• pharmaceutical-grade packaging and traceability;
• stability data and change-control systems;
• customer-specific qualification and audit approval.

A new entrant can manufacture technically acceptable HPMC but still face a long commercial ramp because drug companies must assess equivalence, perform formulation testing, update regulatory files, and manage supply continuity.

What generic launch risks exist for products using HPMC 2910?

HPMC 2910 does not create a direct generic-entry barrier. Its impact is indirect and formulation-specific.

Generic manufacturers may face risk when:

• the reference product depends on a proprietary controlled-release matrix;
• dissolution performance changes with viscosity or particle size;
• the excipient supplier is named in regulatory filings;
• a formulation patent claims a specific polymer ratio or release profile;
• switching suppliers requires substantial comparative dissolution work;
• the product uses a proprietary HPMC coating system;
• a shortage prevents timely scale-up.

For immediate-release products, supplier substitution is often more manageable. For extended-release products, HPMC grade selection can materially affect dissolution and bioequivalence, increasing development risk.

How does HPMC 2910 compare with competing excipients?

Excipient	Main advantage	Main limitation versus HPMC 2910
HPMC 2910	Broad use, film formation, matrix control, vegetarian positioning	Can require grade-specific optimization
HPMC 2906	Useful film-forming and lower-substitution profile	Not interchangeable in every formulation
HPMC 2208	Strong matrix-forming capability	Different hydration and release behavior
Povidone	Effective binder and solubilizer	Less suited to some sustained-release matrices
Ethylcellulose	Strong water-insoluble release barrier	Less hydrophilic and often needs pore-former systems
HPC	Good film formation and solubility	Different thermal and viscosity behavior
Gelatin	Established capsule technology	Animal-derived and less suitable for vegetarian positioning
Pullulan	Capsule and film applications	Higher cost and narrower supplier base in some markets

HPMC 2910 is commercially attractive because one excipient can support several formulation functions. That reduces the number of materials a developer must manage, although it does not eliminate formulation-specific testing.

What licensing deals and litigation affect HPMC 2910?

Publicly visible licensing and litigation activity is concentrated in finished pharmaceutical products, capsule technologies, delivery systems, and proprietary coating formulations rather than in the basic HPMC 2910 material.

There is no widely recognized, industry-wide license controlling ordinary pharmaceutical use of HPMC 2910. Suppliers may enter confidential technology, distribution, manufacturing, or formulation-support arrangements. Such agreements are usually reported only when material to a public company.

Litigation risk is therefore product-specific. A generic company using HPMC 2910 may face litigation over the drug’s formulation or method of use, but the presence of HPMC 2910 alone does not normally create patent infringement exposure.

What is the competitive outlook for HPMC 2910?

The market should remain structurally competitive, with multinational suppliers retaining advantages in regulatory support and global qualification while Asian producers compete through scale and cost.

The most defensible commercial positions are likely to be:

1. Qualified pharmaceutical grades with multinational regulatory support.
2. High-viscosity grades used in complex modified-release products.
3. HPMC capsule-shell supply integrated with capsule manufacturing.
4. Film-coating systems that combine HPMC with pigments, plasticizers, and process support.
5. Dual-region manufacturing that reduces supply interruption risk.

Customer concentration, qualification cycles, and raw-material volatility will limit rapid price increases. Suppliers with broad cellulose-derivative portfolios can offset weakness in pharmaceuticals with food, personal-care, construction, or industrial demand.

Key Takeaways

• HPMC 2910 is a mature, compendial pharmaceutical excipient with broad use in oral solid dosage forms.
• It is identified by CAS 9004-65-3 and a methoxy/hydroxypropoxy substitution profile.
• Demand is driven by generics, film coating, modified-release tablets, vegetarian capsules, and global contract manufacturing.
• The material has no standalone Orange Book exclusivity, Paragraph IV exposure, or biosimilar pathway.
• Competitive advantage rests on manufacturing consistency, regulatory documentation, supply reliability, and technical service.
• Pharmaceutical-grade HPMC 2910 should earn a quality and qualification premium over industrial material.
• Public companies do not generally disclose HPMC 2910 revenue or profitability separately.
• Near-term financial performance is exposed to inventory cycles and raw-material costs; medium-term demand should remain supported by oral solid dosage growth.
• The main IP risks concern finished formulations, release profiles, capsule technologies, and coating systems rather than the basic excipient.
• Generic-entry risk is formulation-specific and is highest in controlled-release products.

FAQs

Is hypromellose 2910 the same as HPMC E5?

Not necessarily. HPMC E5 commonly refers to a low-viscosity grade of substitution type 2910, but grade naming varies by supplier. The substitution type and viscosity specification must both be confirmed.

Is HPMC 2910 suitable for extended-release tablets?

Yes. Higher-viscosity HPMC 2910 grades can form hydrophilic matrices that slow drug release. The appropriate grade depends on drug solubility, dose, tablet geometry, polymer concentration, and target dissolution profile.

Can pharmaceutical manufacturers switch HPMC 2910 suppliers?

Usually, but the change may require comparative testing, supplier qualification, stability assessment, and regulatory documentation. The burden is greater for modified-release and bioequivalence-sensitive products.

Is HPMC 2910 derived from animals?

No. HPMC 2910 is derived from cellulose and is generally used as a plant-based alternative to gelatin in suitable capsule applications.

Does HPMC 2910 have a drug master file?

A supplier may maintain a Drug Master File or equivalent confidential quality file, but the existence and regulatory status of a specific file must be confirmed with the supplier and relevant authority. A DMF does not create market exclusivity.

References

1. United States Pharmacopeial Convention. (2024). Hypromellose monograph. In United States Pharmacopeia and National Formulary (USP-NF). https://www.usp.org
2. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveingredient
3. International Council for Harmonisation. (2024). Q3C(R8): Impurities: Guideline for residual solvents. https://www.ich.org
4. International Council for Harmonisation. (2024). Q3D(R2): Guideline for elemental impurities. https://www.ich.org
5. European Commission. (2024). EudraLex, Volume 4: Good manufacturing practice guidelines. https://health.ec.europa.eu/medicinal-products/eudralex
6. Dow Inc. (2024). 2023 annual report. https://investors.dow.com
7. Ashland Inc. (2024). 2023 annual report. https://investor.ashland.com
8. Shin-Etsu Chemical Co., Ltd. (2024). Annual report 2024. https://www.shinetsu.co.jp/en/ir/
9. Lotte Fine Chemical Co., Ltd. (2024). Annual report and investor materials. https://www.lottefinechem.com en